6401 Hollis Street
About Santen, Inc.
Santen is a global pharmaceutical company focused solely on ophthalmology. We’re committed to serving serious unmet needs by developing innovative solutions that protect vision and, in turn, preserve quality of life for people around the world.
Santen USA, located in Emeryville, CA, is an important part of our ophthalmic research and development efforts worldwide and the home of our regional business teams. By leveraging our deep industry knowledge and a network of external partners, we aim to deliver game-changing therapies and make hope a reality for people facing vision impairment and loss.
Our deep roots start in Japan, Santen’s worldwide headquarters, where the company began in 1890. Since then, Santen has become an established leader in the Asian and European prescription ophthalmology marketplaces and continues to expand across global markets, including the United States. Today, Santen employs more than 3,500 people worldwide and sells specialty ophthalmic products in more than 60 countries.
With a clear focus on vision, we aim to deliver the highest quality products, to act with integrity, to earn the trust of our partners and customers, and to deliver sight-saving innovations to physicians and patients who are waiting for them.
22 articles with Santen, Inc.
Santen Hosts Event to Raise Public Awareness of Importance of Continued Glaucoma Treatment Prior to Sponsoring World Glaucoma Week in March
As part of its efforts to raise public awareness of glaucoma, Santen Pharmaceutical Co., Ltd., based in Osaka, will sponsor glaucoma awareness-raising activities to be conducted around the world during the World Glaucoma Week, from Sunday, March 10, to Saturday, March 16, 2019.
Santen Expands Research and Development Leadership Team with Additions of Reza M. Haque, MD, PhD and Peter Sallstig, MD, MBA
Reza M. Haque, MD, PhD, has been appointed as Senior Vice President, Global Research and Development Strategy, and Peter Sallstig, MD, MBA, has been appointed as Senior Vice President, Global Product Development.
11/5/2018Biopharma companies make key appointments to fill leadership positions. Let's take a look!
Santen Announces Initiation of Phase 3 Clinical Development Program (SPECTRUM) in the United States Evaluating Omidenepag Isopropyl (DE-117) for the Treatment of Glaucoma or Ocular Hypertension
Pivotal Phase 3 development program (SPECTRUM) in the United States, evaluating the investigational use of omidenepag isopropyl (DE-117), a selective agonist for the prostanoid receptor EP2, for the treatment of glaucoma or ocular hypertension (OHT).
Santen Presents Phase I/II Data on DE-122 (Carotuximab) in Patients With Refractory Wet Age-Related Macular Degeneration
No serious adverse events were reported.
The CRL indicates that the FDA is unable to approve the application in its present form and requests additional substantiating evidence to demonstrate efficacy of IVT sirolimus in the treatment of noninfectious uveitis of the posterior segment.
Santen Announces U.S. FDA Filing Acceptance Of New Drug Application (NDA) For Intravitreal Sirolimus (DE-109) In The Treatment Of Non-Infectious Uveitis Of The Posterior Segment
Santen, Inc. Launches IKERVIS - The First And Only Ciclosporin Eye Drops Licensed In The UK, On 27th July 2015
European Medicines Agency Accepts Santen, Inc.'s Marketing Application Filing For Intravitreal Sirolimus For The Treatment Of Noninfectious Uveitis Of The Posterior Segment
DURECT Corporation Enters Into License Agreement Granting Santen, Inc. The Worldwide Rights To A Sustained Release SABER Ophthalmology Product
NicOx SA: Santen, Inc. Grants EuPharmed Extension Of Exclusive Rights To Distribute Cationorm® In Italy
Santen, Inc. Phase 3 Study Meets Primary Endpoint For The Treatment Of Non-Infectious Posterior Segment Uveitis (NI-PSU)
Santen Pharmaceutical Announces the Appointment of Naveed Shams, M.D., Ph.D. as the President and CEO
Santen, Inc. Announces European Medicines Evaluation Agency Orphan Drug Status for Sirolimus (DE-109)
Clinical Data, Inc. Receives Notice of IND Filing by Santen, Inc. and Upcoming $2 Million Milestone Payment for A2A Agonist Development Program Focused on Glaucoma Treatments